Deal Watch: Mylan Shareholders Give Thumbs-Up To Perrigo Acquisition
Executive Summary
Medivation continues its pipeline expansion efforts beyond Xtandi by paying $410m up front for a Phase III PARP inhibitor from BioMarin. Novo Nordisk acquires a pair of diabetes-focused start-ups, while Immatics will establish a US subsidiary on the MD Anderson Cancer Center campus in Houston.
You may also be interested in...
Pfizer Will Retain Infliximab Biosimilar In US After Hospira Acquisition
While European Union requires Pfizer to divest its infliximab candidate in Europe as condition of acquisition, FTC demands only that it sell off four generics.
Supreme Court Seems Ready To Uphold Ruling Against Amgen’s Anti-PCSK9 Antibody Patents
Justices question what Amgen’s invention covers in its dispute with Sanofi. They appear inclined to uphold Federal Circuit’s standard for enablement despite potential negative impact on genus claims.
‘Recipe For Disaster’ In Supplement Manufacturing? US DoJ Attorney Cooks Up Likely Causes
"You end up with a recipe for maybe there's adulterants in the product. Maybe the product wasn't manufactured according to the spec, so it's misbranded. Worse, there could be adulterants. In some of those ingredients, there's a lot of potential failures,” says Patrick Runkle, senior litigation counsel at DoJ Consumer Protection Branch, during FDL conference.